Medline Inc. enters the week of May 18 with a striking divergence: short interest has extended its rebuild to a new recent high, while options traders have turned notably more bullish than at any point in the past month.
The short side kept building through this week. Estimated short interest reached 26.7 million shares by May 19 — up 27% on the week and 17% higher than a month ago, continuing the aggressive rebuild that began around May 7. That follows the pattern flagged last week, when the week-on-week increase was already the sharpest in the tracked series. The pace has not slowed. The ORTEX short score has risen in step, climbing from 46.1 on May 7 to 54.5 by May 19 — a meaningful move in less than two weeks, pushing the reading from neutral into moderately elevated territory. Yet the borrow market still refuses to validate the urgency. Cost to borrow remains anchored near 0.52%, barely moved over the past month. Borrow availability is running at 344% of short interest — well into comfortable territory and up from around 306% a week ago — meaning the lending pool is expanding alongside the short position. There is no squeeze pressure here. The rebuild looks like conviction, not desperation.
Options tell a different story entirely. The put/call ratio has dropped to 0.41, sitting roughly 1.4 standard deviations below its 20-day average of 0.49. That is the most call-heavy positioning in weeks, and a sharp reversal from the mild defensive tilt observed earlier in May. The PCR has been drifting lower since mid-May, with Monday's reading of 0.40 the lowest in the recent window. Options traders are not hedging into the next print — they are reaching for upside.
The Street has spent the past two weeks trimming numbers without abandoning the bull thesis. After the May 6 earnings miss sent the stock down 7.6% on the day and nearly 15% over five days, Citi and Bernstein both lowered targets — to $55 and $54 respectively — while holding Buy and Outperform ratings. BNP Paribas cut its target more aggressively to $40 while keeping a Neutral. The consensus remains firmly bullish: all 15 covering analysts carry Buy-equivalent ratings, and the mean price target of $51.64 implies roughly 37% upside from the current $37.70. The PE multiple has compressed by more than 7 points over 30 days, and the PB ratio has fallen half a turn over the same period — the stock is cheaper than it was before earnings on virtually every measure. Bulls point to the AI-driven Mpower platform and the Symbotic partnership as the long-term margin story. Bears, to the extent they are expressing views through short positions, appear to be questioning the pace of that margin delivery.
The ownership structure adds an important overlay. Carlyle and Hellman & Friedman together offloaded well over $1 billion worth of shares in a single session on March 10. Blackstone trimmed 18.7 million shares as of March 31. Abu Dhabi Investment Authority cut nearly 6.2 million shares in the same period. These are not operational sellers — they are private equity sponsors managing their post-IPO exit programs. On the other side, Fidelity (FMR) added 10.2 million shares, Capital Research added 9.3 million, and Invesco built a new position of 18.4 million shares. Institutional accumulation by active managers is running alongside sponsor distribution — a tug of war that helps explain why the stock has struggled to sustain rallies despite a broadly intact analyst consensus.
The next earnings event is scheduled for June 11. Given that the last two prints produced single-day declines of 6–8% and five-day drawdowns of 13–15%, the upcoming report is the single most important variable for positioning on either side. What to watch between now and then: whether the short interest build continues at its current pace, whether the options market maintains its bullish lean heading into the print, and whether any of the active buyers who added shares in Q1 show signs of adding more at current levels.
See the live data behind this article on ORTEX.
Open MDLN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
